← 返回

如何优化 CAR-T 细胞治疗流程?德国多利益相关方视角下顺畅流程前提条件的群体概念图分析

英文原题:How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.

查看英文原题

How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective.

PubMed 2024/09/23(内容时间) Front Oncol Q2 · IF 3.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

这 80 条陈述凸显了 CAR-T 治疗过程的复杂性和多样性。

中文摘要

开展群体概念绘图(GCM)分析,这是一种混合方法参与式研究。不同专业背景的 CAR-T 专家分三步进行:1)头脑风暴,提出流程顺畅所需的相关因素(陈述);2)根据陈述间的相似性进行分类;3)评价每条陈述的重要性和可行性。研究据此生成反映总体主题的聚类图,并计算每条陈述及各聚类的平均评分。

共有 20 名 CAR-T 专家参与,收集 80 条陈述,形成以下 10 个聚类(平均重要性/可行性):患者和医师信息(4.16/3.77)、支持网络(4.03/3.53)、患者资格(4.41/3.63)、证据、透明度与沟通(4.01/3.33)、文书工作(4.1/2.52)、与制药企业的接口(4.03/2.85)、费用报销(4.29/2.31)、质量管理(4.17/3.18)、CAR-T 诊疗中心基础设施(4.1/2.93)以及以患者为中心的流程(4.46/3.32)。讨论:80 条陈述凸显 CAR-T 治疗流程复杂且涉及多方面内容。我们的结果提供了克服障碍的第一步:识别潜在障碍和必要前提。决策者和相关参与者可利用这些结果制定策略和措施,进一步推动流程顺畅实施。

展开英文摘要原文

A Group Concept Mapping (GCM) analysis, a mixed-methods participatory research, was conducted. CAR-T experts from different professional backgrounds went through three steps: 1) Brainstorming relevant aspects (statements) for a frictionless process, 2) Sorting the collected statements based on their similarity, and 3) Rating the importance and feasibility of each statement. A cluster map reflecting the overarching topics was derived, and mean ratings per statement and cluster were calculated.

Overall, 20 CAR-T experts participated. A total of 80 statements were collected, resulting in a map of the following 10 clusters (mean importance/feasibility): Information for patients and physicians (4.16/3.77), Supportive network (4.03/3.53), Eligibility of patients (4.41/3.63), Evidence, transparency and communication (4.01/3.33), Paperwork (4.1/2.52), Interface with pharmaceutical manufacturer (4.03/2.85), Reimbursement (4.29/2.31), Quality Management (4.17/3.18), Infrastructure of CAR-T clinics (4.1/2.93), and Patient-oriented processes (4.46/3.32). DISCUSSION: The 80 statements underlined the complex and manifold nature of the CAR-T treatment process. Our results reflect the first step in overcoming hurdles: identifying potential hurdles and required preconditions. Decision-makers and stakeholders can use the results to derive strategies and measures to further promote a frictionless process.

论文信息

作者
Siefen AC、Kurte MS、Jakobs F、Teichert M、von Tresckow B、Reinhardt HC、Holtick U、Atta J
第一作者单位
Faculty of Medicine, University of Duisburg-Essen, Essen, Germany.Germany
通讯作者单位
VITIS Healthcare Group, Cologne, Germany.Germany
期刊
Frontiers in oncology2024
原文标识
PubMed 39376984 · DOI 10.3389/fonc.2024.1466803